Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated price target was lowered to $14.00.
Andrew Fein has given his Buy rating due to a combination of factors that highlight the potential of Vigil Neuroscience Inc. The company’s promising biomarker data, particularly regarding the NfL levels, suggests a positive direction for their drug candidate, iluzanebart. This is crucial as the FDA has shown interest in a potential accelerated approval pathway, contingent on robust biomarker data demonstrating the drug’s likelihood to predict clinical benefits.
Additionally, the favorable safety and target engagement profile of VG-3927, as evidenced by the Phase 1 clinical study, supports the company’s advancement to Phase 2 trials. The data indicates strong brain penetration and sustained target engagement, which is promising for its application in Alzheimer’s disease. These factors, combined with Vigil’s strategic plans and the differentiation of their oral small molecule TREM2 agonist, contribute to Fein’s positive outlook and Buy rating for the stock.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $22.00 price target.